Safety and Efficacy of Low-Dose Prasugrel as Part of Triple Therapy With Aspirin and Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

indicated for OAC because of AF who undergo PCI are recommended to receive triple therapy consisting of aspirin, a P2Y12 receptor inhibitor, and an OAC, if they are not at high risk for bleeding. However, triple therapy is associated with a 3to 5-fold increase in total bleeding complications compared with other antithrombotic therapy The management of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) remains a concern. Approximately 5–10% of patients undergoing PCI have concomitant AF1 and require long-term oral anticoagulation (OAC) therapy. Additionally, dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 receptor inhibitor is essential for preventing thrombotic adverse events, such as stent thrombosis (ST), after stent implantation. Thus, patients Editorial p 963